{"id":9440,"date":"2021-04-27T10:15:46","date_gmt":"2021-04-27T17:15:46","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=9440"},"modified":"2021-04-28T10:16:32","modified_gmt":"2021-04-28T17:16:32","slug":"updated-recommendations-from-the-advisory-committee-on-immunization-practices-for-use-of-the-janssen-johnson-johnson-covid-19-vaccine-after-reports-of-thrombosis-with-thrombocytopenia-syndrome","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/04\/27\/updated-recommendations-from-the-advisory-committee-on-immunization-practices-for-use-of-the-janssen-johnson-johnson-covid-19-vaccine-after-reports-of-thrombosis-with-thrombocytopenia-syndrome\/","title":{"rendered":"Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson &amp; Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients \u2014 United States, April 2021"},"content":{"rendered":"<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">The Advisory Committee on Immunization Practices (ACIP) reaffirmed its interim recommendation for use of the Johnson &amp; Johnson vaccine in all persons aged \u226518 years on April 23, 2021 and recommended including a warning that rare clotting events may occur in female vaccine recipients aged 18-49 years. The updated recommendations follow the recommended pause by the FDA and CDC on April 13, 2021 after reports of thrombosis with thrombocytopenia (TTS) among a small number of vaccine recipients, including central venous sinus thrombosis. As of April 21, 2021, 15 reports of TTS have been reported among approximately 8 million Johnson &amp; Johnson vaccine doses.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">A risk-benefit analysis model that guided ACIP recommendations suggested that over 6 months, resuming vaccine use among persons aged \u226518 years (at 50% of administration rate before the pause) could prevent 3,926 to 9,395 COVID-19-related hospitalizations, 928 to 2,236 ICU admissions, and 586 to 1,435 deaths compared with 26 expected cases of TTS. For every 1 million doses administered to women aged 18-49 years, 297 COVID-19-related hospitalizations, 56 ICU admissions, and six deaths could be prevented, compared with 7 expected TTS cases.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">MacNeil et al.\u00a0(Apr 27, 2021). Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson &amp; Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients \u2014 United States, April 2021. MMWR. <\/span><\/i><a href=\"https:\/\/doi.org\/10.15585\/mmwr.mm7017e4\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.15585\/mmwr.mm7017e4<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Advisory Committee on Immunization Practices (ACIP) reaffirmed its interim recommendation for use of the Johnson &amp; Johnson vaccine in all persons aged \u226518 years on April 23, 2021 and recommended including a warning that rare clotting events may occur in female vaccine recipients aged 18-49 years. The updated recommendations follow the recommended pause by&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/04\/27\/updated-recommendations-from-the-advisory-committee-on-immunization-practices-for-use-of-the-janssen-johnson-johnson-covid-19-vaccine-after-reports-of-thrombosis-with-thrombocytopenia-syndrome\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[195,33],"topic":[31],"class_list":["post-9440","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-adverse-effects","tag-vaccines","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9440","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=9440"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9440\/revisions"}],"predecessor-version":[{"id":9441,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9440\/revisions\/9441"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=9440"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=9440"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=9440"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=9440"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}